A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

PURPOSE: The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and recommended phase II dose of an oral drug composed of paclitaxel and HM30181A, which is an inhibitor of P-glycoprotein, in patients with advanced cancers. MATERIALS AND METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyun Jung, Heo, Dae-Seog, Cho, Joo-Youn, Han, Sae-Won, Chang, Hye-Jung, Yi, Hyeon-Gyu, Kim, Tae-Eun, Lee, Se-Hoon, Oh, Do-Youn, Im, Seock-Ah, Jang, In-Jin, Bang, Yung-Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132447/
https://www.ncbi.nlm.nih.gov/pubmed/25038758
http://dx.doi.org/10.4143/crt.2014.46.3.234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132447/
https://www.ncbi.nlm.nih.gov/pubmed/25038758
http://dx.doi.org/10.4143/crt.2014.46.3.234

Ejemplares similares